Gossamer Bio Moves to Eliminate $120M Debt via Convertible Note Exchange — Gossamer Bio, Inc.

Event summary

Gossamer Bio launches exchange offer to convert $200M in 5.00% Convertible Senior Notes due 2027 into new 7.50% Convertible Senior Secured First Lien Notes due 2030.
Existing noteholders supporting the deal hold approximately 75.2% of the outstanding notes.
The exchange offer and consent solicitation will expire on June 16, 2026, with early tender deadline on June 1, 2026.
New notes will bear interest at 7.50% per annum, payable semi-annually in cash.
The transaction requires 98% of noteholders to tender their notes for the exchange to proceed.

The big picture

Gossamer Bio's move to restructure its debt comes as it focuses on the development and commercialization of seralutinib for pulmonary hypertension. The exchange offer aims to reduce financial constraints and extend the maturity of its debt, which is critical for a biopharmaceutical company navigating the high costs and regulatory hurdles of drug development. The transaction underscores the strategic importance of managing debt obligations while advancing its lead product through clinical trials and potential regulatory approvals.

What we're watching

Debt Reduction Impact: How the elimination of $120M in debt will affect Gossamer Bio's financial flexibility and ability to fund seralutinib development.
Noteholder Participation: Whether Gossamer Bio can secure the required 98% participation from noteholders to complete the exchange offer.
Regulatory Approvals: The pace at which Gossamer Bio can obtain stockholder approval for the issuance of common stock related to the new convertible notes.